Ladenburg Thalmann Upgrades Evaxion Biotech to Buy, Announces $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Ahu Demir upgrades Evaxion Biotech (EVAX) from Neutral to Buy and sets a price target of $8.

April 02, 2024 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evaxion Biotech was upgraded from Neutral to Buy by Ladenburg Thalmann analyst Ahu Demir, with a new price target of $8.
Upgrades by analysts, especially from Neutral to Buy, typically signal a positive outlook on the stock, suggesting potential upside. The new price target of $8, significantly above current levels, indicates an expectation of strong growth or recovery, likely leading to increased investor interest and potentially higher stock prices in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100